Mei Mei Hu
Fondatore presso VAXXINITY, INC.
Patrimonio netto: 9 M $ in data 30/04/2024
Profilo
Fondatore di Vaxxinity, Inc., Mei Mei Hu è attualmente presidente, amministratore delegato e direttore di questa società. Il signor Hu è anche nel consiglio di United BioPharma, Inc. Ha ricevuto una laurea presso l'Università della Pennsylvania e una laurea presso la Harvard Law School.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
VAXXINITY INC CLASS A
58.00% | 15/04/2024 | 65 471 228 ( 58.00% ) | 8 M $ | 30/04/2024 |
VAXXINITY INC CLASS B
39.78% | 15/04/2024 | 5 518 961 ( 39.78% ) | 667 794 $ | 30/04/2024 |
Posizioni attive di Mei Mei Hu
| Società | Posizione | Inizio |
|---|---|---|
| VAXXINITY, INC. | Fondatore | 01/01/2014 |
| UNITED BIOPHARMA INC | Direttore/Membro del Consiglio | 01/03/2020 |
Covaxx, Inc.
 Covaxx, Inc. BiotechnologyHealth Technology Covaxx, Inc. is a vaccine development company that focuses on creating vaccines for COVID-19, neurological disorders such as Alzheimer's and Parkinson's diseases, as well as prevalent chronic disorders like migraine and hypercholesterolemia. The private company is based in Dallas, TX, with operations in other locations. Covaxx recently consolidated with United Neuroscience to form a new holding company called Vaxxinity, Inc. Vaxxinity's lead candidate in its pipeline is UB-612, a vaccine candidate to fight SARS-CoV-2. Additionally, Vaxxinity has deployed hundreds of thousands of SARS-CoV-2 ELISA tests, which have received FDA emergency use authorization (EUA). The company was founded in 2020 by Peter H. Diamandis, and the CEO is Mei Mei Hu. | Amministratore Delegato | 01/03/2020 |
Precedenti posizioni note di Mei Mei Hu
| Società | Posizione | Fine |
|---|---|---|
| Shen Lian Biotechnology Co. Ltd. | Direttore/Membro del Consiglio | 01/01/2014 |
| United Neuroscience LLC | Direttore/Membro del Consiglio | - |
Formazione di Mei Mei Hu
| University of Pennsylvania | Undergraduate Degree |
| Harvard Law School | Graduate Degree |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| VAXXINITY, INC. | Health Technology |
| Aziende private | 4 |
|---|---|
United BioPharma, Inc.
 United BioPharma, Inc. Pharmaceuticals: MajorHealth Technology United BioPharma, Inc. engages in the development, manufacture, and sale of monoclonal antibody drug. The company's business activities include the manufacture and sale of western drugs. Its products include trastumab, adalimumab, bevacizumab, rituximab, and omalizumab. The company was founded by Chang Yi Wang on September 30, 2013 and is headquartered in Hsinchu, Taiwan. | Health Technology |
| Shen Lian Biotechnology Co. Ltd. | |
Covaxx, Inc.
Covaxx, Inc. BiotechnologyHealth Technology Covaxx, Inc. is a vaccine development company that focuses on creating vaccines for COVID-19, neurological disorders such as Alzheimer's and Parkinson's diseases, as well as prevalent chronic disorders like migraine and hypercholesterolemia. The private company is based in Dallas, TX, with operations in other locations. Covaxx recently consolidated with United Neuroscience to form a new holding company called Vaxxinity, Inc. Vaxxinity's lead candidate in its pipeline is UB-612, a vaccine candidate to fight SARS-CoV-2. Additionally, Vaxxinity has deployed hundreds of thousands of SARS-CoV-2 ELISA tests, which have received FDA emergency use authorization (EUA). The company was founded in 2020 by Peter H. Diamandis, and the CEO is Mei Mei Hu. | Health Technology |
| United Neuroscience LLC |
- Borsa valori
- Insiders
- Mei Mei Hu
